Evaluation of factors affecting patients' refusal of HCV treatment in a cohort of Egyptian patients

Background Treatment refusal, defined as active refusal of a patient to receive treatment despite physician recommendations, has not been extensively evaluated before in hepatitis C virus in the era of direct acting antivirals. Objective To investigate the reasons for refusal to receive hepatitis C virus treatment in Egypt. Methods an observational study conducted between July 2018 and November 2019 in Egypt. Enrollment was done to all patients who refused to get hepatitis C virus treatment during the national screening and treatment campaign. Reasons for their refusal were identified using a questionnaire as an instrument for data collection. Results Out of the 220 280 Egyptian hepatitis C virus patients who did not show up to start treatment and were contacted to get therapy, only 84 patients (0.038%) refused to receive treatment. The main reason for their refusal was having concerns about treatment (82.14%) and their main concern was the fear of adverse events (85.5%). Other causes of refusal were non-satisfactory experience at treatment centers (13.09%) and patients preferred to receive complementary and alternative medicines (4.7%). Most patients (65.4%) trusted the efficacy of directly acting antivirals for hepatitis C. None of the study participants was found to suffer from any psychiatric morbidity and the average score of the GHQ-12 was 10.7155. Conclusion Proper health education and awareness regarding hepatitis C virus treatment safety and efficacy is needed to increase treatment acceptance rates.

Automated summary

This study investigated the reasons for refusal to receive hepatitis C virus treatment in Egypt. The main reason for refusal was concerns about treatment, particularly the fear of adverse events. Other reasons included non-satisfactory experiences at treatment centers and preference for complementary and alternative medicines. The majority of patients trusted the efficacy of direct acting antiviral treatment for hepatitis C.